Uncategorized

Starton Therapeutics Inc. and Healthwell Acquisition Corp. I to Combine and Create Publicly Traded Leader in Proprietary Continuous Delivery Technology for Cancer Treatments

Uncategorized /

Starton Therapeutics, Inc. and Healthwell Acquisition Corp. today announced that they have entered into a definitive business combination agreement (the “Business Combination Agreement”) pursuant to which, among other things, HWEL Holdings Corp., a newly formed wholly-owned subsidiary of Healthwell (“Pubco”), has agreed to acquire Starton and become a publicly traded company (the “Transaction”).

Starton Therapeutics Inc. and Healthwell Acquisition Corp. I to Combine and Create Publicly Traded Leader in Proprietary Continuous Delivery Technology for Cancer Treatments Read More »

Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference

Uncategorized /

Palatin Technologies, Inc. today announced the presentation of a poster entitled Effectiveness of PL9643 in Treating the Signs and Symptoms of Moderate to Severe Dry Eye Disease: Results From 2 Independent Clinical Trials at the Association of Research in Vision and Ophthalmology (ARVO) Annual Conference.

Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Read More »

NeoDynamics, Inc. Announces U.S. Availability of NEONAVIA, the First and Only Pulse Biopsy Technology, FDA-Cleared in Breast and Axillary Lymph Node Biopsies

Uncategorized /

NeoDynamics, Inc. announced the U.S. availability of NEONAVIA, the first and only biopsy system built on a patented pulse technology for controlled and precise needle insertion.

NeoDynamics, Inc. Announces U.S. Availability of NEONAVIA, the First and Only Pulse Biopsy Technology, FDA-Cleared in Breast and Axillary Lymph Node Biopsies Read More »

Scroll to Top